CTOs on the Move

Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.